Srijan Ranjitkar
Novartis (United States)(US)Novartis (Ireland)(IE)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Bacterial Genetics and Biotechnology, Antibiotics Pharmacokinetics and Efficacy, Pneumonia and Respiratory Infections, Analytical Chemistry and Chromatography
Most-Cited Works
- → Design, Synthesis, and Properties of a Potent Inhibitor ofPseudomonas aeruginosaDeacetylase LpxC(2017)45 cited
- → Identification of Mutations in the mrdA Gene Encoding PBP2 That Reduce Carbapenem and Diazabicyclooctane Susceptibility of Escherichia coli Clinical Isolates with Mutations in ftsI (PBP3) and Which Carry bla NDM-1(2019)33 cited
- → In Vitro Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae(2018)33 cited
- → Morphological Deconvolution of Beta-Lactam Polyspecificity in E. coli(2019)24 cited
- → Target (MexB)- and Efflux-Based Mechanisms Decreasing the Effectiveness of the Efflux Pump Inhibitor D13-9001 in Pseudomonas aeruginosa PAO1: Uncovering a New Role for MexMN-OprM in Efflux of β-Lactams and a Novel Regulatory Circuit (MmnRS) Controlling MexMN Expression(2018)19 cited
- → Impact of InducibleblaDHA-1on Susceptibility of Klebsiella pneumoniae Clinical Isolates to LYS228 and Identification of ChromosomalmplandampDMutations Mediating Upregulation of Plasmid-BorneblaDHA-1Expression(2018)10 cited
- → Mutations Reducing In Vitro Susceptibility to Novel LpxC Inhibitors in Pseudomonas aeruginosa and Interplay of Efflux and Nonefflux Mechanisms(2019)5 cited
- → Beta-lactam polyspecificity in E. coli(2019)1 cited